Juno Therapeutics, Inc. (NASDAQ:JUNO) – Research analysts at Wedbush lifted their Q3 2017 earnings per share estimates for Juno Therapeutics in a report issued on Tuesday. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will earn ($0.96) per share for the quarter, up from their prior forecast of ($1.05). Wedbush has a “Outperform” rating and a $42.00 price target on the stock. Wedbush also issued estimates for Juno Therapeutics’ Q4 2017 earnings at ($0.98) EPS, FY2017 earnings at ($3.69) EPS, Q1 2018 earnings at ($1.00) EPS, Q2 2018 earnings at ($0.97) EPS, Q3 2018 earnings at ($0.99) EPS, Q4 2018 earnings at ($1.09) EPS, FY2018 earnings at ($4.06) EPS, FY2019 earnings at ($4.38) EPS, FY2020 earnings at ($4.08) EPS and FY2021 earnings at ($3.30) EPS.
Juno Therapeutics (NASDAQ:JUNO) last announced its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by $0.24. Juno Therapeutics had a negative net margin of 354.36% and a negative return on equity of 27.10%. The firm had revenue of $21.30 million during the quarter, compared to analysts’ expectations of $15.59 million. During the same quarter in the prior year, the business earned ($0.64) EPS. The company’s quarterly revenue was down 22.8% compared to the same quarter last year.
WARNING: “Wedbush Equities Analysts Boost Earnings Estimates for Juno Therapeutics, Inc. (JUNO)” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2017/08/31/wedbush-equities-analysts-boost-earnings-estimates-for-juno-therapeutics-inc-juno.html.
Other research analysts have also issued reports about the company. Vetr upgraded Juno Therapeutics to a “buy” rating in a research report on Tuesday, May 23rd. BidaskClub upgraded Juno Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, June 20th. Zacks Investment Research upgraded Juno Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 5th. BTIG Research lowered Juno Therapeutics from a “neutral” rating to a “sell” rating and raised their price target for the stock from $12.00 to $23.00 in a research report on Tuesday, June 6th. Finally, FBR & Co restated a “hold” rating on shares of Juno Therapeutics in a research report on Thursday, May 18th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and eight have issued a buy rating to the company. Juno Therapeutics presently has an average rating of “Hold” and a consensus price target of $31.86.
Juno Therapeutics (JUNO) opened at 40.29 on Thursday. The stock’s market cap is $4.23 billion. The stock has a 50 day moving average price of $28.62 and a 200-day moving average price of $25.14. Juno Therapeutics has a 12 month low of $17.52 and a 12 month high of $44.25. Juno Therapeutics also was the target of unusually large options trading on Tuesday. Traders purchased 6,838 put options on the stock. This represents an increase of 977% compared to the typical daily volume of 635 put options.
In other news, Director Anthony B. Evnin purchased 9,000 shares of the company’s stock in a transaction on Tuesday, June 20th. The shares were purchased at an average price of $24.40 per share, with a total value of $219,600.00. Following the purchase, the director now directly owns 66,301 shares of the company’s stock, valued at approximately $1,617,744.40. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Steve Harr sold 8,750 shares of Juno Therapeutics stock in a transaction dated Tuesday, June 27th. The shares were sold at an average price of $30.00, for a total value of $262,500.00. Following the completion of the sale, the chief financial officer now directly owns 736,189 shares in the company, valued at approximately $22,085,670. The disclosure for this sale can be found here. Insiders have sold a total of 8,053,500 shares of company stock worth $217,594,440 in the last ninety days. 15.26% of the stock is currently owned by company insiders.
Several hedge funds have recently added to or reduced their stakes in the stock. The Manufacturers Life Insurance Company increased its stake in Juno Therapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 228 shares in the last quarter. Pacad Investment Ltd. purchased a new stake in Juno Therapeutics during the second quarter valued at about $105,000. QS Investors LLC purchased a new stake in Juno Therapeutics during the second quarter valued at about $135,000. Macquarie Group Ltd. purchased a new stake in Juno Therapeutics during the second quarter valued at about $248,000. Finally, Great West Life Assurance Co. Can increased its stake in Juno Therapeutics by 80.5% in the first quarter. Great West Life Assurance Co. Can now owns 8,518 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 3,800 shares in the last quarter. 70.76% of the stock is currently owned by hedge funds and other institutional investors.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.